Calcitonin salmon - Generic Drug Details

What are the generic drug sources for calcitonin salmon and what is the scope of freedom to operate?

Calcitonin salmon is the generic ingredient in four branded drugs marketed by Sanofi Aventis Us, Amneal, Cipla, Custopharm Inc, Dr Reddys, Fresenius Kabi Usa, Igi Labs Inc, Ph Health, Sagent, Zydus Pharms, Mylan Ireland Ltd, Apotex Inc, Pharmobedient, and Upsher Smith Labs, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

Twelve suppliers are listed for this compound.

Summary for calcitonin salmon

US Patents:	0
Tradenames:	4
Applicants:	14
NDAs:	16
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	10
Clinical Trials:	22
What excipients (inactive ingredients) are in calcitonin salmon?	calcitonin salmon excipients list
DailyMed Link:	calcitonin salmon at DailyMed

Recent Clinical Trials for calcitonin salmon

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Missouri-Columbia	Phase 4
University of Maryland, Baltimore	Phase 4
University of Maryland	Phase 4

See all calcitonin salmon clinical trials

Pharmacology for calcitonin salmon

Drug Class

Calcitonin

US Patents and Regulatory Information for calcitonin salmon

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	CALCITONIN-SALMON	calcitonin salmon	INJECTABLE;INJECTION	209358-001	Nov 10, 2021	AP	RX	No	No
Custopharm Inc	CALCITONIN-SALMON	calcitonin salmon	INJECTABLE;INJECTION	212416-001	May 14, 2021	AP	RX	No	No
Zydus Pharms	CALCITONIN-SALMON	calcitonin salmon	INJECTABLE;INJECTION	215864-001	Mar 4, 2026	AP	RX	No	No
Ph Health	CALCITONIN-SALMON	calcitonin salmon	SPRAY, METERED;NASAL	076979-001	Jun 8, 2009	AB	RX	No	No
Igi Labs Inc	CALCITONIN-SALMON	calcitonin salmon	INJECTABLE;INJECTION	073690-001	Apr 14, 1995		DISCN	No	No
Dr Reddys	CALCITONIN-SALMON	calcitonin salmon	INJECTABLE;INJECTION	215715-001	Apr 11, 2024	AP	RX	No	No
Cipla	CALCITONIN-SALMON	calcitonin salmon	INJECTABLE;INJECTION	213766-001	Sep 20, 2024	AP	RX	No	No

Expired US Patents for calcitonin salmon

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	MIACALCIN	calcitonin salmon	SPRAY, METERED;NASAL	020313-002	Aug 17, 1995
Pharmobedient	MIACALCIN	calcitonin salmon	SPRAY, METERED;NASAL	020313-002	Aug 17, 1995

Market Dynamics and Financial Trajectory for Calcitonin Salmon

Last updated: April 25, 2026

What is calcitonin salmon and where does it sit in therapy?

Calcitonin salmon is a peptide hormone used to treat conditions where calcitonin has clinical value, most prominently postmenopausal osteoporosis and Paget’s disease of bone. It is marketed as salmon calcitonin (synthetic peptide identical or highly similar to native salmon calcitonin), delivered in injectable and, in several markets historically, nasal spray formats.

Therapeutic positioning has shifted over time as:

• Osteoporosis care moved toward bisphosphonates and later denosumab and anabolic agents.
• Clinical preferences favored therapies with clearer long-term fracture risk reductions across broader patient profiles.
• Safety and tolerability scrutiny increased after concerns historically associated with calcitonin class exposure.

How has the calcitonin salmon market evolved?

The market trajectory for calcitonin salmon is shaped by three forces: patent and exclusivity attrition, competitive switching within osteoporosis and bone disease, and regulatory label tightening (pricing pressure and constrained indications).

Demand drivers (structural)

• Osteoporosis indication persistence: calcitonin salmon maintained an osteoporosis role in some jurisdictions even as frontline therapy migrated.
• Paget’s disease continuity in some countries: calcitonin retained use where alternative options and clinical pathways supported calcitonin.
• Formulation availability: injectable and (where present) intranasal options enabled continued prescribing in select patient segments.

Headwinds (structural)

• Loss of growth headroom as newer agents captured market share.
• Shrinking addressable population for calcitonin due to guideline and payer preference shifts toward antiresorptives with stronger evidence for fracture outcomes.
• Increased payer scrutiny: calcitonin salmon’s place in therapy increasingly became substitution-eligible rather than first-line.

Competitive landscape

Calcitonin salmon competes against:

• Alternative osteoporosis therapies: bisphosphonates, denosumab, and anabolic therapies.
• Other calcitonin products: synthetic calcitonin or alternative formulations where available.
• Supportive care and patient-specific regimens: especially in postmenopausal osteoporosis.

What do pricing and access dynamics look like?

Calcitonin salmon has experienced typical mature-and-pressured product dynamics:

• Erosion from generic and biosimilar-style competition, where applicable by molecule and formulation.
• Tender and formulary effects: public procurement cycles and private plan formularies increasingly favor lower net-price options.
• Substitution pressure: physicians and payers route patients to therapies considered more cost-effective for fracture prevention.

Pricing outcomes generally track:

• Volume loss in osteoporosis as prescribers shift.
• Consolidation into narrower indication populations and sequences after first-line failure or intolerance.
• Downward pricing pressure as products age and exclusivity ends.

How do financial returns typically behave for mature calcitonin salmon products?

Calcitonin salmon is a mature, incumbency-heavy asset class where revenue performance is constrained more by market share and net pricing than by clinical expansion.

A typical financial profile for such products includes:

• Declining trend driven by formulary displacement and guideline evolution.
• Flat-to-down unit economics as generics enter and tender pricing reduces margins.
• Budget-driven procurement rather than high-growth uptake.

What is the regulatory and safety backdrop affecting commercial trajectory?

Calcitonin class prescribing has been influenced by safety communications in the broader market. These did not remove calcitonin from the market, but they did increase restrictions and monitoring expectations in many jurisdictions. For commercial trajectory, the impact typically shows up as:

• More conservative use and tighter patient selection.
• Reduced willingness to prescribe where risk-benefit calculus is less favorable.

The net effect is sustained but limited demand, concentrated in patients where calcitonin remains clinically appropriate.

How do financials change by route of administration (injectable vs nasal)?

Market outcomes typically diverge by formulation:

• Injectable products tend to maintain stable demand in patients routed to parenteral therapy, including specific Paget’s treatment pathways.
• Intranasal products face potentially higher utilization volatility due to:
  • patient preference shifts,
  • local supply and regulatory actions, and
  • increased payer pressure when alternatives are preferred.

In mature markets, injectable products often retain a better floor because they remain a direct alternative in established clinical pathways.

What market-size and growth expectations follow from these dynamics?

Given the therapy shift in osteoporosis and mature status of calcitonin salmon, the market typically follows:

• Low-to-mid single-digit to negative growth in mature geographies once displacement effects dominate.
• More stable revenue in jurisdictions where calcitonin has entrenched reimbursement and guideline pathways still include it as an option.
• Greater downside where reimbursement becomes more restrictive and where competing agents are aggressively promoted or reimbursed.

Financial trajectory is usually dominated by:

• net price erosion,
• volume decline from displacement,
• and the degree of substitution to other osteoporosis drugs.

How should an investor or R&D sponsor interpret the revenue curve?

For calcitonin salmon, the expected revenue curve is characterized by:

• Peak-to-decline pattern already played out in most major markets.
• Revenue sensitivity to tender cycles and formulary decisions.
• Limited upside from label expansion, since clinical alternatives now occupy frontline positions and calcitonin’s role is narrower.

For planning and valuation, the commercial model should assume that growth, if any, comes from:

• minor market-share moves within bone disease subsets,
• supply stabilization,
• and optimized contracting, rather than from broad expansion.

---

Key Takeaways

• Calcitonin salmon is a mature peptide therapy with its commercial role concentrated in osteoporosis and Paget’s disease pathways that have faced structural displacement by newer osteoporosis drugs.
• Market dynamics are driven by formulary substitution, net price erosion, and tightened clinical use after safety-related scrutiny across calcitonin class discussions.
• Financial trajectory is typically flat-to-declining, with outcomes determined more by pricing and contracting than by demand expansion.

---

FAQs

1) Is calcitonin salmon primarily an osteoporosis drug today?

It is still used for postmenopausal osteoporosis in multiple markets, but its share is constrained by guideline and payer preference shifts toward other antiresorptives and anabolic options. It also remains relevant for Paget’s disease where it is reimbursed and clinically used.

2) What factor most impacts revenue for calcitonin salmon?

Net pricing and formulary placement tend to dominate, driven by substitution to other osteoporosis therapies and competitive tender dynamics.

3) Does route of administration affect commercial performance?

Yes. Injectable products generally face different utilization patterns than intranasal products, with the latter often more exposed to utilization volatility under changing prescribing and reimbursement behavior.

4) How do safety communications translate into market behavior?

They typically translate into more conservative prescribing, narrower patient selection, and heightened monitoring expectations, which constrain volume growth.

5) Is there meaningful long-term growth potential?

Broad growth potential is limited because calcitonin salmon’s role is narrower within modern osteoporosis care, making the product more exposed to market-share decline rather than indication expansion.

---

References

[1] EMA. Product information for calcitonin salmon-containing medicines (where applicable). European Medicines Agency.
[2] FDA. Drug Safety and Labeling Communications relevant to calcitonin-containing products (historical class-level safety communications). U.S. Food and Drug Administration.
[3] NICE. Guidance on osteoporosis management and bone health pharmacotherapy (guideline framework affecting treatment selection). National Institute for Health and Care Excellence.
[4] International Osteoporosis Foundation. Management of osteoporosis and treatment trends across antiresorptive and anabolic therapies. IOF.
[5] IQVIA Institute for Human Data Science. Global trends in osteoporosis prescribing and market dynamics (broad class-level shifts impacting calcitonin competitiveness). IQVIA.